Alexion Pharmaceuticals Inc.

Significant research activity focuses on glomerular diseases and kidney transplantation complications. The sponsor pursues novel interventions for immunoglobulin A nephropathy, targeting proteinuria reduction and preservation of estimated glomerular filtration rate. Parallel efforts address proliferative lupus nephritis and primary membranous nephropathy, conditions characterized by immune-mediated glomerular injury.

• Antibody-mediated rejection following kidney transplantation
• Delayed graft function prevention
• Cardiac surgery-associated acute kidney injury
• Major adverse kidney events reduction
• Histologic resolution of chronic active rejection

Investigations include cardiopulmonary bypass-related renal protection and strategies to mitigate ischemia-reperfusion injury in transplant recipients, with particular attention to deceased donor kidney complications.

The sponsor maintains an active research program in neuromuscular junction disorders, specifically generalized myasthenia gravis with acetylcholine receptor autoantibodies. Studies evaluate functional outcome improvements using Myasthenia Gravis Activities of Daily Living scores as primary endpoints. Additional neurological focus encompasses neuromyelitis optica spectrum disorder, an aquaporin-4 antibody-mediated inflammatory condition affecting the optic nerves and spinal cord.

• Complement inhibition in acetylcholine receptor-positive myasthenia gravis
• Pediatric neuromuscular disease management
• Relapsing central nervous system inflammatory disorders
• Pharmacokinetic optimization in pediatric populations

Research extends to anti-neutrophil cytoplasmic antibody-associated vasculitis, addressing both newly diagnosed and relapsing disease presentations with novel immunomodulatory approaches.

Substantial therapeutic development addresses hypophosphatasia, a rare inherited metabolic bone disorder caused by deficient tissue-nonspecific alkaline phosphatase activity. Research evaluates both treatment-naïve patients and those previously exposed to enzyme replacement therapy, with endpoints encompassing radiographic outcomes and functional assessments. The portfolio includes investigations of immune-mediated loss of effectiveness and strategies for managing immunosuppressive therapy in affected individuals.

• Chronic hypoparathyroidism with parathyroid hormone analogs
• Serum calcium normalization and active vitamin D management
• Acromegaly treatment in combination with somatostatin analogs
• Insulin-like growth factor-1 level reduction

Endocrine research addresses growth hormone excess and parathyroid hormone deficiency, exploring novel therapeutic mechanisms beyond conventional hormone replacement strategies.

The sponsor pursues innovative approaches to transthyretin amyloid cardiomyopathy, a progressive infiltrative disease characterized by myocardial deposition of misfolded proteins. Research evaluates reduction of all-cause mortality and cardiovascular clinical events in affected populations. Parallel investigations address cardiac light chain amyloidosis, specifically Mayo stage IIIa and stage IIIb disease, examining combination approaches with plasma cell dyscrasia treatment.

• Cardiovascular hospitalization frequency reduction
• BAG3 mutation-associated dilated cardiomyopathy
• Gene therapy approaches for inherited cardiomyopathy
• Overall survival improvement in advanced amyloidosis

Investigations include first-in-human studies of gene therapy vectors for monogenic forms of dilated cardiomyopathy, representing expansion into advanced therapeutic modalities.